Automate Your Wheel Strategy on SNY
With Tiblio's Option Bot, you can configure your own wheel strategy including SNY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SNY
- Rev/Share 17.2983
- Book/Share 30.1835
- PB 1.4073
- Debt/Equity 0.2969
- CurrentRatio 1.0603
- ROIC 0.0612
- MktCap 103105108479.3186
- FreeCF/Share 0.8591
- PFCF 49.2619
- PE 11.3135
- Debt/Assets 0.1676
- DivYield 0.0449
- ROE 0.1236
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | SNY | Barclays | Overweight | Equal Weight | -- | -- | Jan. 6, 2026 |
| Downgrade | SNY | Guggenheim | Buy | Neutral | -- | -- | Dec. 9, 2025 |
| Downgrade | SNY | JP Morgan | Overweight | Neutral | -- | -- | Dec. 8, 2025 |
| Upgrade | SNY | Morgan Stanley | Equal Weight | Overweight | -- | $58 | Sept. 8, 2025 |
| Upgrade | SNY | Deutsche Bank | Hold | Buy | -- | -- | Sept. 2, 2025 |
| Upgrade | SNY | JP Morgan | Neutral | Overweight | -- | -- | Aug. 8, 2025 |
| Initiation | SNY | Exane BNP Paribas | -- | Outperform | -- | $65 | April 15, 2025 |
| Initiation | SNY | Goldman | -- | Neutral | -- | $65 | March 21, 2025 |
| Upgrade | SNY | Deutsche Bank | Sell | Hold | -- | -- | Jan. 30, 2025 |
News
FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children
Published: January 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Sanofi wins FDA priority review to expand Tzield's use to children as young as one, aiming to delay type 1 diabetes progression.
Read More
This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion.
Published: December 24, 2025 by: Barrons
Sentiment: Positive
Sanofi agrees to acquire Dynavax Technologies in an all-cash deal worth $2.2 billion in total equity value.
Read More
Sanofi to acquire US biotech Dynavax for $2.2 billion
Published: December 24, 2025 by: Reuters
Sentiment: Positive
French drugmaker Sanofi has entered into an agreement to acquire U.S. vaccines company Dynavax Technologies Corporation for around $2.2 billion (1.87 billion euros), it said on Wednesday.
Read More
Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal
Published: December 24, 2025 by: WSJ
Sentiment: Positive
The cash deal seeks to strengthen the French drugmaker's immunization portfolio after it suffered setbacks in clinical trials.
Read More
Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline
Published: December 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline Paris, December 24, 2025. Sanofi announced today that it has entered into an agreement to acquire Dynavax Technologies Corporation (Dynavax), a publicly traded vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B®) and differentiated shingles vaccine candidate.
Read More
Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
Published: December 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Paris, December 24, 2025. The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the new drug application of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) in adult patients.
Read More
Press Release: Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia
Published: December 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ITP Approval based on the LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and improvements in other ITP symptoms ITP is a rare disease of complex immune dysregulation leading to lower platelet counts, bleeding, and reduced quality of life Paris, December 23, 2025 – The European Commission has approved Wayrilz (rilzabrutinib), a novel, oral, reversible, Bruton's tyrosine kinase (BTK) inhibitor, as a new treatment for immune thrombocytopenia …
Read More
Sanofi: Information concerning the total number of voting rights and shares - November 2025
Published: December 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority)
Read More
Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation
Published: December 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation Agreement delivers on President Trump's four requests, establishing a framework for lower prices for patients in the US and a tariff-free accord for Sanofi Showcases commitment to US manufacturing, innovation, and economic growth Paris, December 19, 2025. Sanofi today announced an agreement with President Donald J.
Read More
SNY's Rare Disease Drug Efdoralprin Alfa Gets EMA's Orphan Drug Tag
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Sanofi gains EMA Orphan Drug status for efdoralprin alfa, a phase II biologic for AATD-related emphysema with promising dosing data.
Read More
SNY Stock Down on Double Trouble With Multiple Sclerosis Drug
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Negative
Sanofi shares slide after the FDA again delays its review of its MS drug tolebrutinib, and a phase III study fails to hit its primary endpoint.
Read More
Sanofi: Today's Tolebrutinib Setback Shouldn't Worry Shareholders - This Is Why
Published: December 15, 2025 by: Seeking Alpha
Sentiment: Neutral
Sanofi faces a setback as tolebrutinib fails its Phase 3 PPMS trial, halting regulatory pursuit for this indication. Meanwhile, an approval decision on the candidate has also been delayed. SNY's growth remains robust, with Q3 sales up 7% YoY, net income up 10%, and Dupixent driving ~35% of total revenues. Despite pipeline disappointments, SNY expects high single-digit sales and low-double-digit EPS growth for 2025, supported by new drug launches.
Read More
3 Large Drug Stocks to Watch as the Industry Shows Some Recovery
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Positive
In the Large-Cap Pharmaceuticals industry, Lilly, J&J and Sanofi are worth retaining as the industry shows some recovery.
Read More
SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Sanofi/Regeneron's Dupixent wins EU nod for chronic spontaneous urticaria, marking its seventh approved indication across inflammatory diseases in the EU.
Read More
Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors
Published: November 18, 2025 by: Newsfile Corp
Sentiment: Neutral
Burlington, Massachusetts--(Newsfile Corp. - November 18, 2025) - Lifordi Immunotherapeutics, Inc., a clinical-stage biotech company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammatory disorders, today announced a strategic investment from Sanofi Ventures, the venture arm of global healthcare leader Sanofi, and funding from existing investors ARCH Ventures, 5AM Ventures, and Atlas Venture. The new funds bring the total raised to $112 million and support an ongoing Phase 1 study in Rheumatoid Arthritis (RA) designed to evaluate LFD-200, an ADC delivering a potent glucocorticoid (GC) directly to immune cells.
Read More
Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors
Published: November 18, 2025 by: Business Wire
Sentiment: Neutral
BURLINGTON, Mass.--(BUSINESS WIRE)-- #ADCs--Lifordi Immunotherapeutics, Inc., a clinical-stage biotech company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammatory disorders, today announced a strategic investment from Sanofi Ventures, the venture arm of global healthcare leader Sanofi, and funding from existing investors ARCH Ventures, 5AM Ventures, and Atlas Venture. The new funds bring the total raised to $112 million and support an ongoing Phase 1 study in Rhe.
Read More
Sanofi: Is Dupixent Too Successful?
Published: October 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Sanofi delivered strong Q3 results despite currency headwinds. The company's dependence on Dupixent is increasing. A broad immunology pipeline and the Blueprint Medicines acquisition should help address the issue.
Read More
Sanofi Q3: Cash-Rich, Cheap, And Loading 2026 Shots On Goal
Published: October 24, 2025 by: Seeking Alpha
Sentiment: Positive
Sanofi (SNY) remains a Buy, driven by Dupixent's robust growth and expanding indications, notably with the recent COPD launch. SNY's Q3 saw total revenues rise 7% CER to €12.43 billion, with Dupixent contributing over €4 billion for the first time. Beyond Dupixent, SNY is diversifying with specialty launches like Altuviiio in hemophilia and Beyfortus in RSV, plus a strong pipeline and share buybacks.
Read More
Sanofi (SAN:CA) Q3 2025 Earnings Call Transcript
Published: October 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Sanofi (SAN:CA) Q3 2025 Earnings Call Transcript
Read More
Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline
Published: October 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Sanofi's Q3 earnings top forecasts as Dupixent surges past EUR 4B in sales, offsetting weakness in vaccines.
Read More
SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Neutral
Sanofi's efdoralprin alfa meets all key endpoints in a global phase II study, showing potential as a first restorative recombinant therapy for AATD.
Read More
A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff
Published: September 26, 2025 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk, Sanofi, and AstraZeneca face the largest dollar exposure to President Trump's new 100% tariff on imported branded drugs. NVO's heavy reliance on U.S. sales and imported GLP-1 products puts over 50% of its free cash flow at risk, despite ongoing U.S. manufacturing expansion. Sanofi's high-margin Dupixent and AZN's broad U.S. portfolio are also vulnerable, though both are investing in U.S. production to seek exemptions.
Read More
Sanofi Expands Insulin Savings Program To Cover All US Patients
Published: September 26, 2025 by: Benzinga
Sentiment: Positive
The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA's (NASDAQ: SNY) Genzyme Corporation.
Read More
Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Published: September 23, 2025 by: Seeking Alpha
Sentiment: Neutral
Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Read More
SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.
Read More
FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Neutral
The FDA extends SNY's tolebrutinib NDA review by three months, with decision now expected on Dec. 28, 2025.
Read More
Press Release: EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
Published: September 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary and key secondary endpoints in biologic-naïve patients compared to placebo at week 16 Dual-target Nanobody® VHH inhibiting TNF and OX40L being explored across a range of immune-mediated diseases Reaffirms Sanofi's commitment to addressing underlying inflammation across complex, heterogeneous chronic skin diseases Paris, September 17, 2025. New data from the HS-OBTAIN phase 2a study (clinical study identifier: NCT05849922) show that treatment with brivekimig led to clinically meaningful improvements in the primary endpoint of Hidradenitis Suppurativa Clinical …
Read More
SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.
Read More
Sanofi market value tanks following weak results on eczema drug trials
Published: September 04, 2025 by: Fast Company
Sentiment: Negative
Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after late-stage trial data for its experimental inflammatory disease drug amlitelimab disappointed Wall Street.
Read More
Why Is Sanofi Stock Falling Thursday?
Published: September 04, 2025 by: Benzinga
Sentiment: Negative
On Thursday, Sanofi SA SNY stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company's ability to sustain its dermatology franchise once patent protections expire.
Read More
About Sanofi (SNY)
- IPO Date 2002-07-01
- Website https://www.sanofi.com
- Industry Drug Manufacturers - General
- CEO Paul Hudson
- Employees 82878